Standout Papers

Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial 2024 202653
  1. Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial (2024)
    Kang Wang, Yan‐Jun Xiang et al. Nature Medicine

Citation Impact

3 from Science/Nature 67 standout
Sub-graph 1 of 20

Citing Papers

EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
2024 Standout
New promises and challenges in the treatment of advanced non-small-cell lung cancer
2024 Standout
2 intermediate papers

Works of Yingyi Qin being referenced

Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial
2024 Standout
Maintenance Therapy With Continuous or Switch Strategy in Advanced Non-small Cell Lung Cancer
2011

Author Peers

Author PRM Epidemiology Surgery Oncology Last Decade Papers Cites
Yingyi Qin 245 250 203 216 58 1.2k
Jun Bi 33 181
Hung-Min Chang 1 3 11 310
Axel Doenecke 21 66 155 69 20 408
Sagar H. Patil 4 2 2 1 16 606
Matthew V. Holt 31 25 12 87 20 563

All Works

Loading papers...

Rankless by CCL
2026